Ensign Peak Advisors Inc Acquires 194,673 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Ensign Peak Advisors Inc raised its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 108.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 374,673 shares of the company's stock after buying an additional 194,673 shares during the period. Ensign Peak Advisors Inc owned about 0.49% of Nurix Therapeutics worth $7,059,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. US Bancorp DE increased its holdings in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $87,000. Summit Investment Advisors Inc. lifted its position in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the period. BNP Paribas Financial Markets purchased a new position in Nurix Therapeutics during the 4th quarter worth approximately $164,000. Finally, ADAR1 Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter worth $207,000.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $382,092.92. This represents a 15.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now directly owns 61,516 shares of the company's stock, valued at approximately $707,434. The trade was a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,838 shares of company stock valued at $221,500. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Trading Down 2.2%

Shares of NASDAQ NRIX traded down $0.21 during midday trading on Monday, reaching $9.35. The company's stock had a trading volume of 77,637 shares, compared to its average volume of 875,002. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The company has a 50 day moving average price of $11.07 and a 200 day moving average price of $16.80. The company has a market cap of $712.88 million, a price-to-earnings ratio of -3.23 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The business had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the previous year, the business earned ($0.76) EPS. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NRIX has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Stephens reiterated an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Leerink Partners assumed coverage on Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 target price for the company. JPMorgan Chase & Co. cut their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Finally, Wells Fargo & Company decreased their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.